AstraZeneca: Head to Head Study Reveals Esomeprazole is More Effective Compared to Pantoprazole in Healing Reflux Esophagitis; Results from the EXPO Study Presented Today
MADRID, Spain--(BUSINESS WIRE)--Nov. 5, 2003--Acid control is closely related to the healing of esophagitis. Esomeprazole 40mg (Nexium(R)) is the first PPI offering more effective acid control vs all other PPIs including pantoprazole - translating into better clinical outcomes as shown by the results of the EXPO study released today.
In the acute healing part of the study, esomeprazole 40mg once-daily provides more effective healing of erosive esophagitis after 4 weeks - 80.9% and 74.5% respectively (p less than 0.0001) and faster symptom relief when compared to pantoprazole 40mg once-daily. Furthermore, healing rates were higher from mild to severe grades of erosive esophagitis thus offering better treatment to patients across the spectrum of the disease.
Results from this head to head randomised, international multicentre, double-blind study reveal that patients treated with esomeprazole achieved significantly higher healing rates and experienced sustained resolution of heartburn throughout the 4 weeks treatment. Patients in the esomeprazole treatment group also achieved sustained resolution of heartburn 2 days faster than those treated with pantoprazole. Significantly more patients treated with esomeprazole 40mg achieved complete resolution of heartburn and dysphagia symptoms after 4 weeks compared with those treated with pantoprazole.
Commenting on the study, Dr Joachim Labenz of the Jung-Stilling Krankenhaus, Siegen, Germany said "Our study clearly shows that esomeprazole provides superior clinical efficacy in terms of healing and symptom resolution in patients with reflux esophagitis". He went on to say "In previous comparative studies, Nexium(R) has been shown to provide more effective healing of erosive esophagitis and faster symptom control vs omeprazole and lansoprazole - this combined with the new EXPO data demonstrates the clear clinical benefits attributed to the more effective acid control profile of Nexium(R) vs other PPIs. 1,2,3,4,5
Notes to editors:
The EXPO study is a management study with an initial healing phase. The study is a comparison of Esomeprazole 40mg once-daily and Pantoprazole 40 mg once-daily for the healing of reflux esophagitis. It will be presented as a poster at the United European Gastroenterology Federation Annual Congress on 5th November 2003.
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $17.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index.
To learn more about Nexium(R), please visit our interactive website: www.astrazenecapressoffice.com.
(1)Miner P et al. Gastroenterology 2003;1(24) Suppl 1:A229.
(2)Lind T et al. Aliment Pharmacol Ther. 2000;14:861-867.
(3)Rohss K et al. Dig Dis Sci. 2002 May;47(5):954-8.
(4)Richter JE et al. Am J Gastroenterol. 2001;96:656-65.
(5)Kahrilas PJ et al. Aliment Pharmacol Ther. 2000;14:1249-1258.
Asa Pehrsson, Global PR Manager GI
Tel: +46 (0) 31 706 55 20
Phone +44 207 395 7100